	US 12,187,783 B2
	Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins
Hq Han, Thousand Oaks, CA (US); and Xiaolan Zhou, Newbury Park, CA (US)
Assigned to AliveGen Inc, Grand Cayman (KY)
Filed by AliveGen Inc., Grand Cayman (KY)
Filed on Dec. 7, 2021, as Appl. No. 17/544,579.
Application 17/544,579 is a continuation of application No. 16/343,366, abandoned, previously published as PCT/US2017/057351, filed on Oct. 19, 2017.
Claims priority of provisional application 62/410,595, filed on Oct. 20, 2016.
Prior Publication US 2022/0332791 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/71 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 19/08 (2006.01); A61P 21/00 (2006.01)

CPC C07K 14/71 (2013.01) [A61K 45/06 (2013.01); A61P 19/08 (2018.01); A61P 21/00 (2018.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

8 Claims

1. An isolated hybrid activin IIB receptor (ActRIIB) ligand trap protein comprising a hybrid soluble activin IIB receptor-extracellular domain (ActRIIB-ECD) polypeptide, wherein said hybrid soluble ActRIIB-ECD polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 3-37 and 51-104.